Folate biosynthetic pathway

The Folate biosynthetic pathway comprises a series of enzymatic reactions that produce folate (vitamin B9) derivatives, which are essential cofactors in one-carbon transfer reactions. These reactions support synthesis of purines and thymidylate for DNA, amino acid metabolism, and methylation processes critical for cell function and differentiation[1][2][4][6]. The pathway is present in plants, fungi, protozoa, and bacteria, but absent in animals. Drugs targeting this pathway (sulfonamides, trimethoprim, methotrexate) exploit the fact that humans rely on dietary folate, allowing selective inhibition in pathogens or cancer cells[2][5][1]. Key enzymes within this pathway, such as dihydropteroate synthase and dihydrofolate reductase, are well-recognized therapeutic targets for antimicrobials and anticancer agents. Disruption of folate biosynthesis or utilization leads to severe consequences, including birth defects, anemia, neurodevelopmental disorders, and increased infection risk[6][5]. In summary, "Folate biosynthetic pathway" is not a molecule or receptor but a group of enzymes and reactions critically involved in health and disease, commonly targeted by specific classes of drugs. If you seek information about a single target (such as "dihydrofolate reductase"), clarification is recommended.

Other names

Folate synthesis pathwayFolic acid biosynthesisTHF biosynthetic pathwayde novo folate synthesis

Enzyme inhibition (competitive or non-competitive inhibition of key pathway enzymes, e.g., dihydropteroate synthase, dihydrofolate reductase); Antimetabolite action (blocking folate utilization for DNA synthesis and cell division)